NASDAQ
26.06.26 | 21:59
6,390 US-Dollar
-0,78 % -0,050
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.06. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Shattuck Labs drops 6%, prices $75M share raise at $4 per share | 1 | Seeking Alpha | ||
| 10.06. | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | 236 | AFX News | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen | |
| 10.06. | Shattuck Labs prices $75M public offering at $4 per share | 1 | Investing.com | ||
| 10.06. | Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs commences public offering of common stock | 2 | Investing.com | ||
| 09.06. | Shattuck Labs launches proposed public offering of common stock | 1 | Seeking Alpha | ||
| 09.06. | Shattuck Labs, Inc. Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs receives $54.9M from warrant exercises | 1 | Investing.com | ||
| 09.06. | Shattuck Labs secures $54.9M from warrant exercises, extends cash runway into 2029 | 1 | Seeking Alpha | ||
| 09.06. | Shattuck Labs, Inc.: Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update | 168 | GlobeNewswire (Europe) | AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class... ► Artikel lesen | |
| 08.06. | Why Is Shattuck Labs Stock Trading Lower On Monday? | 1 | Benzinga.com | ||
| 08.06. | Shattuck Labs reports phase 1 data for DR3 blocking antibody | 1 | Investing.com | ||
| 08.06. | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 1 Results for SL-325 | 606 | GlobeNewswire (Europe) | Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of... ► Artikel lesen | |
| 05.06. | Shattuck Labs to present phase 1 data for SL-325 on Monday | 3 | Investing.com | ||
| 05.06. | Shattuck Labs: Vorstellung von Phase-1-Studiendaten zu SL-325 am Montag | 1 | Investing.com Deutsch | ||
| 05.06. | Shattuck Labs, Inc.: Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 | 2 | GlobeNewswire (USA) | ||
| 02.06. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | Shattuck Labs GAAP EPS of -$0.13 in-line | 2 | Seeking Alpha | ||
| 07.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights | 344 | GlobeNewswire (Europe) | Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 -Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,265 | -0,04 % | VALNEVA SE: Valneva Announces Successful Outcome of its Annual General Meeting | Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that... ► Artikel lesen | |
| VIVOSIM LABS | 1,030 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,030 | 0,00 % | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | -3,86 % | NurExone bringt Entwicklung, Finanzierung und US-Ausbau voran | ||
| SAREPTA THERAPEUTICS | 14,660 | -1,08 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| XOMA ROYALTY | 37,400 | +0,54 % | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,460 | -2,23 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| TRAWS PHARMA | 0,840 | +1,57 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| UNIQURE | 41,600 | -0,48 % | uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| ZAI LAB LTD ADR | 16,100 | +1,90 % | ZAI LAB (09688): NEXT DAY DISCLOSURE RETURN | ||
| TRINITY BIOTECH | 0,353 | -2,33 % | Trinity Biotech plc: Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market | - New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance... ► Artikel lesen | |
| VERASTEM | 3,234 | -2,44 % | RBC Kapital bestätigt Rating für Verastem: G12D-Inhibitor mit über 250 % Kurspotenzial | ||
| VOYAGER THERAPEUTICS | 2,944 | -5,28 % | Voyager Therapeutics, Inc.: Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease | - Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 2,120 | +41,33 % | Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update | Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular... ► Artikel lesen |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,390 Euro und damit -0,78 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.